GLP-1 Weight Loss Boca Raton: Approved, Not Compounded
Most GLP-1 weight loss Boca Raton advertising still describes a world that ended in 2025, when the legal ground under compounded copies of these medicines moved out from underneath them. That is the most useful thing to know before you hand over a card, so it is the first thing on this page rather than the last.
GLP-1 medications are prescription medicines that act on the receptor for glucagon-like peptide-1, a gut hormone involved in appetite and food intake. The FDA-approved injectable for chronic weight management in this class is semaglutide, sold as Wegovy. Its higher-dose form, Wegovy HD 7.2 mg, was approved on 19 March 2026.
Tirzepatide, sold as Zepbound, is routinely lumped in with them and is not quite the same drug. The FDA’s own approval announcement describes it acting on two receptors — GLP-1 and GIP. That difference is why the two medicines are not interchangeable and why choosing between them is a clinical decision rather than a price comparison.
GLP-1 weight loss Boca Raton: what the medicines actually are
Start with the category itself, because it is used loosely and the looseness hides a real distinction.
Glucagon-like peptide-1 is a hormone the gut releases after eating. The medicines named after it act at its receptor and reduce appetite and food intake. Semaglutide is the one that belongs in the class without qualification, and for chronic weight management it is approved as Wegovy. In March 2026 the FDA approved a higher-dose version, Wegovy HD at 7.2 mg, described as being for adults with obesity, or overweight with at least one weight-related condition.
Semaglutide also carries something no other medicine in this space has. On 8 March 2024 the FDA approved Wegovy “to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight”. That is a cardiovascular outcome indication, not a weight claim, and for some patients it is the reason to prefer this molecule over the other one.
Now the distinction. Tirzepatide, approved as Zepbound on 8 November 2023, is described by the FDA as activating receptors for two intestinal hormones, GLP-1 and GIP. Calling it a GLP-1 drug is shorthand, and the shorthand costs you something: the two medicines have different mechanisms, different trial results and different side-effect profiles. Anywhere that presents them as the same product at two prices is not choosing between them on your behalf.
Each has its own page here, written separately for that reason — semaglutide Boca Raton, which works through what the Wegovy label records, and tirzepatide Boca Raton.
The compounding rules changed, and most pages have not caught up
This is the part worth reading twice, because it is recent, it is checkable, and a lot of advertising in South Florida still describes a world that ended.
Compounded copies of the GLP-1 medications became widespread for one specific reason: while a drug sits on the FDA shortage list, compounders may prepare versions of it. Both drugs were on that list. Then both came off. The FDA re-evaluated and declared the tirzepatide shortage resolved on 19 December 2024, and the semaglutide shortage resolved on 21 February 2025.
The agency set wind-down dates — for tirzepatide, 18 February 2025 for 503A pharmacies and 19 March 2025 for 503B outsourcing facilities; for semaglutide, 22 April and 22 May 2025. Those dates were then overtaken. Litigation in Outsourcing Facilities Association v. FDA produced rulings on 5 March 2025 for tirzepatide and 24 April 2025 for semaglutide that terminated the enforcement discretion periods altogether.
The practical upshot is plain. The shortage-based route that made mass-market compounded semaglutide and tirzepatide lawful is closed. A clinic still selling a compounded copy today is not operating under the exception it was originally operating under, and it is fair to ask which basis it believes it is using.
None of this makes compounding itself improper. Compounding has real and legitimate uses — this practice uses compounded preparations in hormone care, and says so on the hormone page. What changed is narrower and specific to these two molecules.
Why GLP-1 weight loss Boca Raton care here uses the approved product
There is a safety argument alongside the regulatory one, and it is the FDA’s, not ours.
On 26 July 2024 the agency issued an alert about dosing errors with compounded injectable semaglutide, and the detail is worth having. Patients drawing from multiple-dose vials administered “five to 20 times more than the intended dose” — in one example, 50 units drawn on an insulin syringe where five were intended. Separately, clinicians converting between milligrams and units prescribed “five to 10 times more than the intended dose”: 25 units instead of 5, and 20 units instead of 2, the latter affecting three patients. The reported effects included nausea and vomiting, fainting, dehydration, acute pancreatitis and gallstones, and the FDA states some patients required hospitalisation. It does not publish a total count, so neither will we.
Read the mechanism of those errors rather than the drama of them. Almost every one is a measurement error: a vial, a syringe, and a conversion done by hand. The FDA-approved products are not supplied that way. They arrive as pens holding a fixed, labelled dose, which removes the arithmetic that produced those reports. That is the practical reason this practice prescribes the approved product, and it is a better reason than brand preference.
What you get here is a prescription medicine dispensed through a pharmacy, in a labelled pen, with the manufacturer’s own instructions in the box. What you will not get is a cheaper vial and a syringe, and if price is the deciding factor you should know that before you book rather than after.
How weight loss medication is actually run at Brazelia MedSpa
The medicine is the smallest part of the programme, which is the opposite of how it is usually sold.
Whether either drug is appropriate at all is a clinical judgement made in person, against your history, your current medicines and your labs. No page can make it, and any site that offers you a product before that conversation has skipped the only step that matters. You will not find a dose, a titration schedule or a candidacy rule anywhere on this page for the same reason.
What the visit does cover is the surrounding picture, which is where most weight programmes quietly fail. Thyroid function and hormones can hold weight in place regardless of the medication — those are looked at on the thyroid and bioidentical hormone pages. Baseline and interval bloods sit under metabolic labs. Because these medicines reduce intake, protein and muscle become the thing to defend, which is why nutrition coaching and body composition tracking run alongside rather than afterwards — scale weight alone will not tell you whether you are losing fat or muscle.
And there is an after. What happens when the medication stops is a real question, handled on the weight maintenance page. The wider programme this sits inside is set out under wellness programs.
That whole picture is what GLP-1 weight loss Boca Raton care is supposed to mean, and it is the reason the programme is not sold as a monthly injection price.
New patients start with a consultation. You will hear what each label supports, what it does not, and what the plan would look like, before anything is prescribed.
Frequently asked questions
Is compounded semaglutide or tirzepatide still legal?
The shortage-based route that made it widespread has closed. The FDA declared the tirzepatide shortage resolved on 19 December 2024 and semaglutide on 21 February 2025, and court rulings in March and April 2025 terminated the enforcement discretion periods. Source 4.
Is tirzepatide a GLP-1 medication?
Not exactly. The FDA describes Zepbound as activating receptors for two intestinal hormones, GLP-1 and GIP. It is commonly grouped with the GLP-1 medications, but the mechanism differs and so do the trial results. Source 1.
Which one is better, semaglutide or tirzepatide?
That is a clinical decision, not a web answer. Semaglutide is the one carrying an FDA cardiovascular indication, approved 8 March 2024 to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and obesity or overweight, which matters for some patients and not others. Sources 1 and 2.
Why does the approved product cost more than a compounded vial?
Because it is a different thing: a manufactured, labelled pen dispensed through a pharmacy rather than a preparation drawn from a vial. The FDA dosing-error alert of 26 July 2024 describes what the vial-and-syringe route produced in practice. Source 5.
What dose would I be on?
Not something this page will tell you. Dosing is prescribing, it depends on your history and your labs, and it is decided in consultation with the clinician who signs for it.
What happens when I stop taking it?
It is the question to ask before starting rather than after. Appetite effects are tied to the medicine, so the plan for coming off it is part of the plan for going on it, and that is set out on the weight maintenance page.
Do you offer these without an in-person visit?
No. Whether either medicine is appropriate is assessed in person against your history, your current medicines and your bloods, and that assessment is the point of the programme. Patients travel in from across South Florida for it rather than ordering online.
Sources and how this page was built
The approvals, indications and mechanism descriptions on this page are taken from the FDA’s own announcements for Zepbound (8 November 2023), the Wegovy cardiovascular indication (8 March 2024) and Wegovy HD (19 March 2026). Shortage resolution dates, the 503A and 503B wind-down dates and the termination of enforcement discretion are read from the FDA compounding policy page, updated 1 April 2026. The dosing-error figures are quoted from the FDA alert of 26 July 2024, including its own statement that a total number of reports is not given. All read 28 September 2026. No dose, titration schedule or candidacy criterion is published here, because that is prescribing and it belongs in the consulting room.
- FDA. FDA approves new medication for chronic weight management — Zepbound (tirzepatide), 8 November 2023, describing action at both the GLP-1 and GIP receptors. fda.gov
- FDA. FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight — Wegovy, 8 March 2024. fda.gov
- FDA. FDA approves fourth product under national priority voucher programme, higher dose semaglutide — Wegovy HD 7.2 mg, 19 March 2026. fda.gov
- FDA. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize — shortage resolution dates and the termination of enforcement discretion, page updated 1 April 2026. fda.gov
- FDA. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products, 26 July 2024. fda.gov
Why patients choose Brazelia MedSpa
This page is the best answer we can give, and it costs us something to write. The easy version advertises a low monthly price on a compounded vial and does not mention that the shortages ended. This one publishes the dates, explains why the approved pen is used here, and tells you plainly that it is the more expensive option. Patients who book after reading it know what they are buying.
The programme is run by Khali Reed, CRNA, APRN, in a practice under the medical direction of Dr. Herbert R. Slavin, MD, on site rather than a name on a licence.
Brazelia MedSpa has treated patients from the same address in downtown Boca Raton for 18 years, near Mizner Park, and sees patients from across South Florida, from Delray Beach and Boynton Beach to Deerfield Beach and Fort Lauderdale. The programme is run by the same people every visit, which matters more on a medication you take for a year than on a treatment you have once.
Weight is also rarely treated as just weight here. Because Brazelia MedSpa runs hormone, metabolic, skin and regenerative programmes under one roof, thyroid, sleep, training load and the skin changes that follow a large weight reduction can be looked at in the same place, by people who are already talking to each other.
New patients start with a consultation, and nothing is prescribed on a first visit unless it is clinically appropriate and you want to proceed. You will hear what the label supports, what it does not, and what the plan would look like before anything is decided.
This page describes what published labels, regulatory records and peer-reviewed research report about these treatments. It is general health information, not medical advice, and it is not a substitute for a consultation. Whether any treatment is appropriate for you is a clinical judgement that depends on your history and examination.
Talk through whether a GLP-1 medication fits your situation
New patients start with a consultation, where your history, your labs and what each label actually supports are discussed before anything is prescribed.